Top

Published in:

Open Access 01-06-2015 | Osteocytes (T Bellido and J Klein-Nulend, Section Editors)

IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism?

Authors: Astrid D. Bakker, Richard T. Jaspers

Published in: Current Osteoporosis Reports | Issue 3/2015

Abstract

Insulin-like growth factor 1 (IGF-1) and interleukin 6 (IL-6) play an important role in the adaptation of both muscle and bone to mechanical stimuli. Here, we provide an overview of the functions of IL-6 and IGF-1 in bone and muscle metabolism, and the intracellular signaling pathways that are well known to mediate these functions. In particular, we discuss the Akt/mammalian target of rapamycin (mTOR) pathway which in skeletal muscle is known for its key role in regulating the rate of mRNA translation (protein synthesis). Since the role of the mTOR pathway in bone is explored to a much lesser extent, we discuss what is known about this pathway in bone and the potential role of this pathway in bone remodeling. We will also discuss the possible ways of influencing IGF-1 or IL-6 signaling by osteocytes and the clinical implications of pharmacological or nutritional modulation of the Akt/mTOR pathway.

Goodship AE, Lanyon LE, McFie H. Functional adaptation of bone to increased stress. An experimental study. J Bone Joint Surg Am. 1979;61(4):539–46.PubMed

Tanck E, Bakker AD, Kregting S, Cornelissen B, Klein-Nulend J, Van Rietbergen B. Predictive value of femoral head heterogeneity for fracture risk. Bone. 2009;44(4):590–5.CrossRefPubMed

Cheung WY, Simmons CA, You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone. 2012;50(1):104–10.CrossRefPubMed

Taylor AF, Saunders MM, Shingle DL, Cimbala JM, Zhou Z, Donahue HJ. Mechanically stimulated osteocytes regulate osteoblastic activity via gap junctions. Am J Physiol Cell Physiol. 2007;292(1):C545–52.CrossRefPubMed

Bakker AD, Klein-Nulend J, Tanck E, Heyligers IC, Albers GH, Lips P, et al. Different responsiveness to mechanical stress of bone cells from osteoporotic versus osteoarthritic donors. Osteoporos Int. 2006;17(6):827–33.CrossRefPubMed

Jaspers RT, Bravenboer N. Biochemical interaction between muscle and bone: a physiological reality? Clin Rev Bone Miner Metab. 2014;12:27–43.CrossRef

Shen H, Grimston S, Civitelli R, Thomopoulos S. Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice. J Bone Miner Res. 2014. doi:10.1002/jbmr.2389.

Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40(6):1544–53.CrossRefPubMedCentralPubMed

Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 2009;44(1):17–23.CrossRefPubMedCentralPubMed

10.

Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Urena-Torres P, et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014;2(5):427–36.CrossRefPubMed

11.•

Juffer P, Bakker AD, Klein-Nulend J, Jaspers RT. Mechanical loading by fluid shear stress of myotube glycocalyx stimulates growth factor expression and nitric oxide production. Cell Biochem Biophys. 2014;69(3):411–9. This is the first study showing that muscle cells, like osteocytes, respond to pulsating fluid shear stress by producing NO as well as IL-6 and Cox2.CrossRefPubMed

12.

Juffer P, Jaspers RT, Klein-Nulend J, Bakker AD. Mechanically loaded myotubes affect osteoclast formation. Calcif Tissue Int. 2014;94(3):319–26.CrossRefPubMed

13.

Ardawi MS, Rouzi AA, Qari MH. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012;97(10):3691–9.CrossRefPubMed

14.

Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: Mechanisms for activation and possible biological roles. Faseb J. 2002;16(11):1335–47.CrossRefPubMed

15.

Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529(Pt 1):237–42.CrossRefPubMedCentralPubMed

16.

Hamrick MW, McNeil PL, Patterson SL. Role of muscle-derived growth factors in bone formation. J Musculoskelet Neuronal Interact. 2010;10(1):64–70.PubMedCentralPubMed

17.

Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature. 1982;296(5854):252–3.CrossRefPubMed

18.

Stewart CE, Rotwein P. Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996;76(4):1005–26.PubMed

19.

Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology. 2005;20:232–8.CrossRefPubMed

20.

Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141(7):2674–82.PubMed

21.

Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 1997;138(9):3849–58.PubMed

22.

Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology. 1988;122(1):254–60.CrossRefPubMed

23.

Deng M, Zhang B, Wang K, Liu F, Xiao H, Zhao J, et al. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop. 2011;35(7):1099–106.CrossRefPubMedCentralPubMed

24.

Hill PA, Reynolds JJ, Meikle MC. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology. 1995;136(1):124–31.PubMed

25.

Wang Y, Nishida S, Sakata T, Elalieh HZ, Chang W, Halloran BP, et al. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology. 2006;147(10):4753–61.CrossRefPubMed

26.

Canalis E, McCarthy T, Centrella M. Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae. Endocrinology. 1988;122(1):22–7.CrossRefPubMed

27.•

Elis S, Courtland HW, Wu Y, Rosen CJ, Sun H, Jepsen KJ, et al. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res. 2010;25(6):1257–66. This study demonstrates that overexpression of IGF-1 in livers of IGF-1 null mice elevated serum IGF-1. This did not overcome skeletal deficiencies during neonatal and early postnatal growth, but did fully compensated for the absence of locally produced IGF-1 between 4 and 16 weeks of age.

28.

Sheng MH, Zhou XD, Bonewald LF, Baylink DJ, Lau KH. Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. Bone. 2013;52(1):133–44.CrossRefPubMed

29.•

Juffer P, Jaspers RT, Lips P, Bakker AD, Klein-Nulend J. Expression of muscle anabolic and metabolic factors in mechanically loaded MLO-Y4 osteocytes. Am J Physiol Endocrinol Metab. 2012;302(4):E389–95. This study shows osteocytes subjected to a pulsating fluid shear stress produce muscle anaboic growth factors IGF-1, MGF, VEGF, HGF but not myostatin. This indicates a high similarity in mechanotransduction between muscle fiber and osteocytes.

30.

Reijnders CM, Bravenboer N, Tromp AM, Blankenstein MA, Lips P. Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia. J Endocrinol. 2007;192(1):131–40.CrossRefPubMed

31.••

Lau KH, Baylink DJ, Zhou XD, Rodriguez D, Bonewald LF, Li Z, et al. Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. Am J Physiol Endocrinol Metab. 2013;305(2):E271–81. This study demonstrates that conditional disruption of IGF-1 in osteocytes abolishes the loading-induced activation of the Wnt signaling and the corresponding osteogenic response.CrossRefPubMed

32.

Heinemeier KM, Olesen JL, Schjerling P, Haddad F, Langberg H, Baldwin KM, et al. Short-term strength training and the expression of myostatin and IGF-I isoforms in rat muscle and tendon: differential effects of specific contraction types. J Appl Physiol. 2007;102(2):573–81.CrossRefPubMed

33.

Mills P, Dominique JC, Lafreniere JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007;7(10):2247–59.CrossRefPubMed

34.

Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1–3):156–60.CrossRefPubMed

35.

Jaspers RT, van Beek-Harmsen BJ, Blankenstein MA, Goldspink G, Huijing PA, van der Laarse WJ. Hypertrophy of mature Xenopus muscle fibres in culture induced by synergy of albumin and insulin. Pflugers Arch. 2008;457(1):161–70.CrossRefPubMed

36.

Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, et al. Skeletal muscle hypertrophy is mediated by a Ca2 + -dependent calcineurin signalling pathway. Nature. 1999;400(6744):576–81.CrossRefPubMed

37.

Glass DJ. A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways. Cancer Cell. 2005;8(5):351–2.CrossRefPubMed

38.••

Bakker AD, Kulkarni RN, Klein-Nulend J, Lems WF. IL-6 alters osteocyte signaling toward osteoblasts but not osteoclasts. J Dent Res. 2014;93(4):394–9. This study demonstrates that treatment of osteocytes with IL-6 in vitro does neither alters the osteocyte response to mechanical stimuli nor the communication towards osteoclast precursors.CrossRefPubMed

39.

Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians. 1998;110(6):559–74.PubMed

40.

Dame JB, Juul SE. The distribution of receptors for the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 in the developing human fetus. Early Hum Dev. 2000;58(1):25–39.CrossRefPubMed

41.

Dallas DJ, Genever PG, Patton AJ, Millichip MI, McKie N, Skerry TM. Localization of ADAM10 and Notch receptors in bone. Bone. 1999;25(1):9–15.CrossRefPubMed

42.

Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13(5):1189–96.PubMedCentralPubMed

43.

Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res. 2011;26(8):1891–903.CrossRefPubMedCentralPubMed

44.

Duplomb L, Baud’huin M, Charrier C, Berreur M, Trichet V, Blanchard F, et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: Key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology. 2008;149(7):3688–97.CrossRefPubMed

45.

Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995;182(5):1461–8.CrossRefPubMed

46.

Abu-Taha M, Rius C, Hermenegildo C, Noguera I, Cerda-Nicolas JM, Issekutz AC, et al. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol. 2009;183(2):1393–402.CrossRefPubMed

47.

Yang X, Ricciardi BF, Hernandez-Soria A, Shi Y, Pleshko Camacho N, Bostrom MP. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone. 2007;41(6):928–36.CrossRefPubMedCentralPubMed

48.

Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997;138(9):3666–76.PubMed

49.

Erices A, Conget P, Rojas C, Minguell JJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res. 2002;280(1):24–32.CrossRefPubMed

50.

Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;280(17):4131–48.CrossRefPubMedCentralPubMed

51.

Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA, Pedersen BK. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. J Physiol. 2000;528(Pt 1):157–63.CrossRefPubMedCentralPubMed

52.

Croisier JL, Camus G, Venneman I, Deby-Dupont G, Juchmes-Ferir A, Lamy M, et al. Effects of training on exercise-induced muscle damage and interleukin 6 production. Muscle Nerve. 1999;22(2):208–12.CrossRefPubMed

53.

Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab. 2002;283(6):E1272–8.CrossRefPubMed

54.

Pedersen BK, Edward F. Adolph distinguished lecture: muscle as an endocrine organ: IL-6 and other myokines. J Appl Physiol. 2009;107(4):1006–14.CrossRefPubMed

55.

Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005;98(3):911–7.CrossRefPubMed

56.

Washington TA, White JP, Davis JM, Wilson LB, Lowe LL, Sato S, et al. Skeletal muscle mass recovery from atrophy in IL-6 knockout mice. Acta Physiol (Oxf). 2011;202(4):657–69.CrossRefPubMedCentral

57.

Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7(1):33–44.CrossRefPubMed

58.

Spangenburg EE, Bowles DK, Booth FW. Insulin-like growth factor-induced transcriptional activity of the skeletal alpha-actin gene is regulated by signaling mechanisms linked to voltage-gated calcium channels during myoblast differentiation. Endocrinology. 2004;145(4):2054–63.CrossRefPubMed

59.

Bolster DR, Kimball SR, Jefferson LS. Translational control mechanisms modulate skeletal muscle gene expression during hypertrophy. Exerc Sport Sci Rev. 2003;31(3):111–6.CrossRefPubMed

60.

Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472–87.CrossRefPubMedCentralPubMed

61.

Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett. 1998;421(2):125–30.CrossRefPubMed

62.

Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004;14(3):395–403.CrossRefPubMed

63.••

Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012;18(7):1095–101. Recent study showing that IGF-1 released from the bone matrix by osteoclasts affects differentiation of osteoblast precursors via mTOR.CrossRefPubMedCentralPubMed

64.

Chen J, Tu X, Esen E, Joeng KS, Lin C, Arbeit JM, et al. WNT7B promotes bone formation in part through mTORC1. PLoS Genet. 2014;10(1):e1004145.CrossRefPubMedCentralPubMed

65.••

Santos A, Bakker AD, Zandieh-Doulabi B, de Blieck-Hogervorst JM, Klein-Nulend J. Early activation of the beta-catenin pathway in osteocytes is mediated by nitric oxide, phosphatidyl inositol-3 kinase/Akt, and focal adhesion kinase. Biochem Biophys Res Commun. 2010;391(1):364–9. This work provides evidence that mechanical loading of osteocytes activates the PI3K/Akt signalling pathway in these cells.CrossRefPubMed

66.

Wang Z, Guo J. Mechanical induction of BMP-7 in osteocyte blocks glucocorticoid-induced apoptosis through PI3K/AKT/GSK3beta pathway. Cell Biochem Biophys. 2013;67(2):567–74.CrossRefPubMed

67.

Kitase Y, Lee S, Gluhak-Heinrich J, Johnson ML, Harris SE, Bonewald LF. CCL7 is a protective factor secreted by mechanically loaded osteocytes. J Dent Res. 2014;93(11):1108–15.CrossRefPubMed

68.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143–59.CrossRef

69.

Kurosaka M, Machida S. Interleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targeting. Cell Prolif. 2013;46(4):365–73.CrossRefPubMed

70.

Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol. 2006;20(12):3364–75.CrossRefPubMed

71.

Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab. 2005;289(2):E251–7.CrossRefPubMed

72.•

White JP, Puppa MJ, Gao S, Sato S, Welle SL, Carson JA. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab. 2013;304(10):E1042–52. This study shows that exposure of IL-6 to muscle fibers or myotubes attenuates phopho mTOR levels via activation of AMPK which is independent of STAT1 activity.CrossRefPubMedCentralPubMed

73.

Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38(4):168–76.CrossRefPubMedCentralPubMed

74.

Hardie DG. Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc Nutr Soc. 2011;70(1):92–9.CrossRefPubMed

75.

Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002;277(27):23977–80.CrossRefPubMed

76.

Tong JF, Yan X, Zhu MJ, Du M. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J Cell Biochem. 2009;108(2):458–68.CrossRefPubMed

77.

Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am J Physiol Endocrinol Metab. 2007;292(6):E1555–67.CrossRefPubMed

78.

De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142(11):4818–26.CrossRefPubMed

79.

Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297–314.PubMedCentralPubMed

80.

Tominaga H, Maeda S, Hayashi M, Takeda S, Akira S, Komiya S, et al. CCAAT/enhancer-binding protein beta promotes osteoblast differentiation by enhancing Runx2 activity with ATF4. Mol Biol Cell. 2008;19(12):5373–86.CrossRefPubMedCentralPubMed

81.

Franchimont N, Gangji V, Durant D, Canalis E. Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. Endocrinology. 1997;138(12):5248–55.PubMed

82.

Iyer VV, Kadakia TB, McCabe LR, Schwartz RC. CCAAT/enhancer-binding protein-beta has a role in osteoblast proliferation and differentiation. Exp Cell Res. 2004;295(1):128–37.CrossRefPubMed

83.

Smink JJ, Tunn PU, Leutz A. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPbeta - MafB axis. J Mol Med (Berl). 2012;90(1):25–30.CrossRef

84.

Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab. 2007;293(2):E453–9.CrossRefPubMed

85.••

Smith GC, Ong WK, Costa JL, Watson M, Cornish J, Grey A, et al. Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J. 2013;280(21):5337–49. This study clearly demonstrates the adverse effects of PI3K and mTOR inhibitors on bone metabolism, thereby supporting an important role for these pathways in osteoblast biology.CrossRefPubMed

86.•

Pantovic A, Krstic A, Janjetovic K, Kocic J, Harhaji-Trajkovic L, Bugarski D, et al. Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. Bone. 2013;52(1):524–31. Elegant study showing that RNA interference-mediated silencing of AMPK, mTOR or autophagy-essential LC3β, as well as pharmacological inhibitors of AMPK, Akt, mTOR, and autophagy, suppressed dental pulp-derived mesenchymal stem cell differentiation to osteoblasts.CrossRefPubMed

87.

Srinivas V, Bohensky J, Zahm AM, Shapiro IM. Autophagy in mineralizing tissues: Microenvironmental perspectives. Cell Cycle. 2009;8(3):391–3.CrossRefPubMedCentralPubMed

88.

Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford, England). 2014;53(5):900–3.CrossRef

89.

Alzghoul MB, Gerrard D, Watkins BA, Hannon K. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. Faseb J. 2004;18(1):221–3.PubMed

90.

Deldicque L, Sanchez Canedo C, Horman S, De Potter I, Bertrand L, Hue L, et al. Antagonistic effects of leucine and glutamine on the mTOR pathway in myogenic C2C12 cells. Amino Acids. 2008;35(1):147–55.CrossRefPubMed

91.

Suryawan A, Jeyapalan AS, Orellana RA, Wilson FA, Nguyen HV, Davis TA. Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. Am J Physiol Endocrinol Metab. 2008;295(4):E868–75.CrossRefPubMedCentralPubMed

Title: IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism?
Authors: Astrid D. Bakker
Richard T. Jaspers
Publication date: 01-06-2015
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 3/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-015-0264-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Bone Cells and Bone Turnover in Diabetes Mellitus

Sclerostin and CKD-MBD

Bone Imaging and Fracture Risk Assessment in Kidney Disease

GNAS Spectrum of Disorders

Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors

Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease